SpeechVive Inc.

SpeechVive Inc. is a healthcare technology company specializing in innovative wearable devices designed to improve speech for individuals with Parkinson’s disease, enhancing communication and quality of life. SpeechVive Inc. was founded in 2011 in Lafayette, US.

The company develops wearable devices that assist individuals with Parkinson's disease in enhancing their speech capabilities. The firm has undergone 4 different funding rounds, with the most recent being a VENTURE DEBT round in August 2018, raising USD 0. 28 mn, bringing the total amount raised to USD 0. 98 mn.

The CEO of SpeechVive is Steve Mogensen. SpeechVive specializes in the development and distribution of a wearable speech device designed specifically for individuals with Parkinson’s disease. This innovative product functions by automatically triggering the brain to enhance speech volume, clarity, and pacing during verbal communication. The primary use case for SpeechVive is to improve the quality of life for patients by facilitating easier and more effective conversations, thereby reducing the stress often associated with speech difficulties.

The device eliminates the need for intensive therapy, serving as an alternative to traditional behavioral treatment programs that can last for several weeks. The target clientele includes Parkinson's patients, their caregivers, and healthcare providers, particularly speech-language pathologists. SpeechVive's products are marketed primarily in the United States, with potential outreach to other regions as the company expands its presence in the healthcare technology sector. SpeechVive generates revenue through direct sales of its wearable speech devices to patients and healthcare professionals, as well as partnerships with Medicare, the Veterans Administration, and various commercial insurance plans.

The company's transaction structure includes direct-to-consumer sales, where individuals purchase the SpeechVive device either through online channels or healthcare providers. The pricing model typically involves a one-time purchase of the device, which may be covered partially or fully by insurance providers. The flagship product, the SpeechVive device, is tailored to deliver immediate results in improving speech functionality for users, promoting enhanced communication in both personal and professional settings. This emphasis on quick, effective outcomes significantly contributes to patient satisfaction and retention.

In August 2018, SpeechVive Inc. raised USD 0. 28 mn in VENTURE DEBT financing, aimed at supporting the development of new products and expansion into new markets. The company plans to enhance its product offerings designed for individuals with speech difficulties, focusing on innovative features that augment user experience.

Additionally, SpeechVive is targeting expansion into international markets to reach a broader audience, although specific regions and timelines have not been disclosed.